Opinion
Video
This program was possible with support from Bayer.
Improving Clinical Trials in Prostate Cancer
Author(s):
Practical advice for improving clinical trials to ensure they are more reflective of the overall population of patients with prostate cancer.
This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute; Rashid K. Sayyid, MD, MSc, of the University of Toronto; and Reginald Tucker-Seeley, MA, ScM, ScD, of ZERO Prostate Cancer.
Dr Reginald Tucker-Seeley discusses decades-long efforts to increase minority representation in trials. He advises against assumptions that minorities lack interest, instead directly asking them to participate. Reviewing inclusion/exclusion criteria to avoid disproportionate exclusion of racial/ethnic groups is also key. Educating minority communities that trials facilitate treatment access and presenting health systems as trustworthy partners can further engagement. Alleviating financial barriers through organizational assistance allows wider participation despite potential travel needs.
Dr Tucker-Seeley adds physicians sometimes erroneously assume patients will decline trials or mistrust recommendations, so patients should inquire about available options. He notes many first turn to “Dr. Google” for information, making patient resources on clinical trials from credible organizations like ZERO vitally important for contextualizing the process and guiding navigation.
In summary, Dr Reginald Tucker-Seeley outlines multifaceted approaches to enhance minority clinical trial participation, including direct outreach, inclusive criteria, financial/logistics support, community education and trust-building, questioning assumptions that drive physician inaction, and providing patient resources from reputable groups.
*Video synopsis is AI-generated and reviewed by CURE editorial staff.
